Faculty of Health: Medicine, Dentistry and Human Sciences

School of Health Professions

2022-10-04

# Handgrip Strength Index: a Novel Parameter which quantifies clinical weakness in people on haemodialysis.

## Dilloway, T

http://hdl.handle.net/10026.1/19845

10.1053/j.jrn.2022.08.002 Journal of Renal Nutrition Elsevier

All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.

Handgrip Strength Index: a Novel Parameter which quantifies clinical weakness in people on haemodialysis.

Tina Dilloway, MSc, RD, Dr Damien R. Ashby, PhD FRCP, Mary Hickson, RD PhD, Prof, Ayako Temple, MRes, RD, Dr Lina R. Johansson, RD PhD

PII: S1051-2276(22)00166-2

DOI: https://doi.org/10.1053/j.jrn.2022.08.002

Reference: YJREN 51888

To appear in: Journal of Renal Nutrition

Received Date: 15 April 2022

Revised Date: 25 June 2022

Accepted Date: 31 August 2022

Please cite this article as: Dilloway T, Ashby DR, Hickson M, Temple A, Johansson LR, Handgrip Strength Index: a Novel Parameter which quantifies clinical weakness in people on haemodialysis., *Journal of Renal Nutrition* (2022), doi: https://doi.org/10.1053/j.jrn.2022.08.002.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.



1	Handgrip Strength Index: a Novel Parameter which quantifies clinical weakness
2	in people on haemodialysis.
3	
4	
5	Tina Dilloway MSc, RD; Dr Damien R Ashby PhD FRCP; Prof Mary Hickson RD PhD;
6	Ayako Temple MRes, RD; Dr Lina R Johansson RD PhD <sup>†</sup>
7	
8	Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK (TD,
9	DRA, AT, LJ)
10	Plymouth Institute of Health Research, University of Plymouth, UK (MH)
11	
12	<sup>†</sup> Lina Johansson is corresponding author (Department of Nutrition and Dietetics,
13	Hammersmith Hospital, Du Cane Road W12 0HS, London UK,
14	l.johansson@imperial.ac.uk, +44 203 313 3947)
15	Abstract: 282 words
16	Body of manuscript: 3073
17	Short title: Handgrip strength in adults on haemodialysis
18	
19	Acknowledgements
20	We would like to thank the renal dietetic team at Imperial College Healthcare NHS
21	Trust for diligently helping to collect all this data in particular Claire Ahmad, Thushara
22	Dassanayake, Nevine El-Sherbini, Ruth Kander and Stella Kourtellidou as well as
23	Anna Vrakas.

#### 24 Support and financial disclosure

25

#### 26 Conflict of Interest Statement

- 27 Dr. Johansson has received speaker fees from Abbott.
- 28 Dr Ashby has nothing to disclose.
- 29 Prof Mary Hickson has received speaker fees from Fresenius.
- 30 Tina Dilloway has received speaker fees from B.Braun.
- 31 Ayako Temple has nothing to disclose.
- 32
- 33

#### 34 Funding statement

35 Imperial Health Charity and the NIHR Imperial Biomedical Research Centre (BRC)

- 36 supported Dr Lina Johansson through a fellowship for time to complete the
- 37 manuscript. Imperial Health Charity provided funding for Tina Dilloway's time to
- complete the study. The funding bodies were not involved in the design of the study
- 39 or the collection, analyses and interpretation of data, nor in the writing of the
- 40 manuscript.

1	Handgrip Strength Index: a Novel Parameter which quantifies clinical weakness
2	in people on haemodialysis.
3	
4	
5	Abstract: 282 words
6	Body of manuscript: 3073
7	Short title: Handgrip strength in adults on haemodialysis
8	
9	Acknowledgements
10	Support and financial disclosure
11	
12	Conflict of Interest Statement
13	
14	
15	Funding statement
16	The funding bodies were not involved in the design of the study or the collection,
17	analyses and interpretation of data, nor in the writing of the manuscript.

18

## Journal Pre-proof

#### 19 Abstract

20 Objective: Muscle strength in people on haemodialysis is associated with nutritional status, quality of life, functional independence and survival. Handgrip Strength 21 (HGS) is simple to measure, but clinical interpretation is limited by the lack of 22 reference ranges for a haemodialysis population. This study aims to define a novel 23 parameter, HGS index, which quantifies degree of clinical weakness specific to a 24 haemodialysis population and to test if this predicts survival. 25 Methods: In a cross-sectional single centre study HGS was measured in stable 26 participants on haemodialysis. HGS in the well-nourished subgroup, was used to 27 28 develop a predictive equation for "expected" HGS according to demographic variables. This then was compared to observed HGS resulting in HGS index (%), an 29 individualised parameter indicating weakness due to clinical variables whilst 30 31 accounting for demographic weakness contributors to strength. The association between HGS index and survival was explored in all participants. 32 Results: Amongst 427 well-nourished individuals on haemodialysis, HGS was 33 strongly associated with demographic variables and predicted in males by the 34 equation: HGS(kg) = 0.38\*height(cm) - 0.31\*age(years) - 18, and in females by the 35 equation: HGS(kg) = 0.25\*height(cm) - 0.11\*age(years) - 16. Amongst 547 36 participants (22% with protein energy wasting), lower HGS index was associated 37 with diabetes (p=0.004), lower body mass index (p=0.005), lower albumin (p=0.033) 38 and longer dialysis vintage (p=0.007). Over a mean observation period of 2.8 years, 39 quintile of HGS index was strongly associated with survival (p=0.023), and in a Cox 40 Proportional Hazards model, the independent predictors of mortality were age, 41 albumin, body mass index and HGS index. 42

43 Conclusion: HGS index, defined as observed relative to expected HGS, is an

individualised measure of clinical weakness. It is a novel parameter which 44

independently predicts survival. HGS index improves the detection of clinically 45

- relevant muscle weakness in people on haemodialysis, opening up the possibility of 46
- earlier, individualised interventions and improving outcomes in this vulnerable group. 47
- 48
- Keywords: handgrip; haemodialysis, equation, nutritional status, renal 49

al stat

#### 50 Introduction

Despite gradual progress over the last decade, mortality in people on haemodialysis 51 52 remains high, with many centres reporting median survival around 5 years for people in their 60's <sup>1</sup>. Protein energy wasting, noted in 28-54% of people on haemodialysis, 53 could be a contributor to this as it is associated with decreased quality of life and 54 increased hospitalization<sup>2</sup>. A key feature of the clinical diagnosis of protein energy 55 wasting is the determination of muscle mass <sup>3</sup>. However, research has demonstrated 56 that muscle strength is more strongly associated with the risk of mortality than 57 58 muscle mass in people on haemodialysis <sup>4,5</sup>. Therefore muscle mass alone is not a proxy for strength and therefore muscle quality (ratio of strength to mass) may be 59 better at describing the physiological changes in muscle that occur with aging <sup>6</sup>. 60 Handgrip Strength (HGS) is a functional measure which has been linked to 61 nutritional decline <sup>7,8</sup> and mortality in people on dialysis <sup>9</sup>, and outside dialysis has 62 been used to predict mortality <sup>10</sup> and old age disability <sup>11</sup>. Functional measures are 63 often the earliest to exhibit change when the clinical condition deteriorates, and are 64 closely linked to other important outcomes, such as ability to self-care and live 65 independently <sup>12</sup>. HGS is cheap and easy to measure and may be useful for early 66 detection of protein energy wasting, as well as a potential surrogate outcome 67 measure for interventional studies. In addition, HGS is often used in evaluation of 68 sarcopenia, in particular in older people on dialysis <sup>13,14</sup>. In these studies, a wide 69 range of cut-offs and reference ranges are used to determine weakness that is 70 beyond aging, exposing a gap in the determination of the presence sarcopenia and 71 potentially frailty. 72

Abnormal HGS may be defined by deviation from reference ranges <sup>15–17</sup>, often
stratified by factors such as age, gender, height and ethnicity <sup>18,19</sup>. Additionally HGS

cut-off values have been used to identify clinically relevant (26 and 16kg) and 75 mobility limiting (30 and 20kg) weakness in males and females over 65, respectively 76 <sup>20 21</sup>. These reference ranges are problematic when applied to HGS values from 77 people on haemodialysis as they have been derived from community dwelling 78 populations and thereby generally reflect weakness of aging. As such, the values 79 from people on haemodialysis fall predominantly within the weakest categories as 80 81 the inherent clinical weakness and reduced function associated with being on haemodialysis is unaccounted for, thereby leading to a nonspecific tool with limited 82 83 clinical applications. Haemodialysis specific HGS cut-offs have been used to help identify malnutrition <sup>22</sup> and predict mortality <sup>5</sup> e.g. 28.3kg for males and 23.4kgs for 84 females <sup>5</sup>. However, they are based on crude gender categories without further 85 demographic characterisation according to variables that are strong determinants of 86 HGS e.g. age, height. It is challenging in a study of n=436 to produce reference 87 ranges for all variables which is the approach undertaken in large population studies 88 such as Spruit's UK biobank study with over 500,000 participants <sup>17</sup> which provides 89 HGS ranges for several discrete demographic categories (age, height, sex). An 90 alternative approach is to develop a predictive equation that determines "expected" 91 HGS from demographic features, which can overcome the need to have thousands 92 of participants for every subcategory. Currently, without haemodialysis-specific 93 normative values, abnormal HGS is only obvious in the individual through repeated 94 measures and noting a decline over time, which is how renal clinical guidelines 95 recommend its clinical usage <sup>23</sup>. 96

The lack of reference ranges highlights an important knowledge and clinical
assessment gap to be addressed. The aims of this study are: (1) to determine the
demographic variables that influence HGS in a well-nourished haemodialysis

population; (2) to determine a prediction equation to calculate an individual's

"101 "expected" HGS from these demographic variables; (3) to define a novel,

demographically adjusted parameter, HGS index, as the observed HGS as a

103 percentage of the expected HGS to determine degree of clinical weakness observed;

and (4) to test if HGS index predicts survival in this group.

105

#### 106 Methods

In this cross-sectional study, clinically stable adults were recruited from nine satellite
haemodialysis units in an urban mixed-ethnicity renal centre in XXX. Adults (aged
18 years or older) were eligible if receiving dialysis for at least three months, without
hospital admission in the previous month, able to consent, did not have a fistula in
their dominant arm and able to stand for HGS measurement.

112

#### 113 Data collection

HGS was measured once in each participant, immediately prior to a haemodialysis 114 session, to avoid dialysis-associated fatigue <sup>24</sup> which leads to a weakening of 115 maximal grip over the session <sup>25,26</sup>. HGS was measured in the dominant non-fistula 116 hand, using a Jamar® Hand Dynamometer (Sammons Preston, Bolingbrook, Illnois, 117 US). Measurements were undertaken under standard testing conditions: in the 118 standing position, with elbow at full extension, and palm facing inwards, with people 119 supporting themselves as necessary with their free arm. This standing position was 120 selected as opposed to the sitting position as the chair available (e.g. with arms, 121 without arms) is likely to vary between dialysis units. To allow participants to 122 become familiar with the dynamometer, a training (warm up) measurement preceded 123 the single recorded HGS measurement. This is thought to result in an increased grip 124

strength and could reflect a truly physiological maximum <sup>27</sup>. It has also been shown 125 to be as reliable and instigate less pain than the best of (or mean of) two or three 126 127 trials <sup>28,29</sup>. A unique assessment feature of this study was including a recording for pain. As this group are vulnerable to hand conditions such as carpal tunnel, pain 128 was recorded on a 100mm visual analogue scale before and after measurements: 129 130 those with pain scores above 20mm (value selected by researchers) were excluded, since pain confounds the measurement of maximal strength <sup>30</sup>. It was felt to be 131 important by the authors to determine if significant pain was influencing an 132 133 individual's maximal grip and to exclude these values. 134 Participants were divided into well and poorly nourished groups using the seven-135

point Subjective Global Assessment (SGA). SGA is a well validated global

137 nutritional assessment tool used to determine if a person is well-nourished (score 6-

138 7), mildly to moderately malnourished (score 3-5) or severely malnourished (score 1-

139 2) <sup>31</sup>. Demographic and clinical data were also recorded.

140

141

#### 142 Statistical analyses

143 This study was powered so that several groups (age > or  $\leq$  65 years, ethnic

144 background of black, white and asian and gender) would be well represented.

145 Enough dialysis shifts were targeted with the aim to recruit at least 500 people in

146 total (anticipating at least 20% of this sample to have protein energy wasting).

147 This study size was determined so that the subgroups of age > or  $\leq$  65 years, ethnic

148 background of Black, White and Asian; and gender would be well represented. A

sample size of 30 is commonly considered sufficient (based loosely on the

convergence of normal and t-distributions) for representative parameter estimation in
a predictive equation. The study sample size was designed by anticipating protein
energy wasting in 20% of participants, a total sample size of 500 was therefore
selected to achieve at least 30 well-nourished participants in each of the 12 planned
subgroups.

155

Initial HGS analysis was restricted to well-nourished people (SGA 6 or 7) to define 156 "expected" HGS in well-nourished, relatively stable, individuals on haemodialysis 157 158 from demographics. Demographic variables associated with HGS were explored with 5-fold k-fold cross-validation, which separates training and validation subgroups 159 to ensure development of a generalisable model, but without loss of data <sup>32,33</sup>. The 160 well-nourished group was first separated by gender and then randomly split into five 161 subgroups: for each subgroup, linear regression was used to define predictors of 162 HGS in the remaining well-nourished patients (with the subgroup removed), with 163 prediction by the final resulting model tested and thereby validated in the subgroup 164 (which did not contribute to model development). The mean of each coefficient 165 averaged over An average of these five models was used to provide the coefficients 166 for the prediction equation. Coefficient accuracy (number of significant figures) was 167 selected so that increased accuracy would improve R<sup>2</sup> by less than 0.01. The aim of 168 this stage was to define "expected" HGS in well-nourished dialysis patients, so only 169 demographic predictors (such as age, gender, height and ethnicity) were assessed, 170 and variables influenced by illness (such as comorbid conditions, weight and 171 albumin) were not included. 172

173

174 Subsequently, a novel parameter, HGS index, was defined to quantify the degree of

175 HGS clinical weakness, by comparison with the expected HGS for a stable, well-

nourished individual of the same age, height and gender. HGS index was therefore

defined as the ratio of observed to expected HGS, expressed as a percentage.

178

Simple HGS and HGS index were compared using multivariable linear regression in the whole group, in order to define the extent to which each overlaps with clinical and demographic predictors of weakness. Kaplan-Meier survival analysis was used to demonstrate the effect of HGS index on survival, and Cox Proportional Hazards models were used to compare HGS and HGS index as independent predictors of survival, alongside other risk factors.

185

There was minimal missing data (dialysis vintage was unknown for two participants and was coded as two years). SPSS v25.0 (IBM, New York) was used for survival and regression analyses.

189

#### 190 *Ethics*

This study was approved by the XXX and was performed in accordance with the Declaration of Helsinki, with written informed consent from all participants.

193

#### 194 **Results**

Between May 2010 and June 2015, HGS was measured in 547 participants (aged

196 18-92, 52% male), of whom 427 (78.1%) were considered to be well-nourished, with

197 SGA score 6 or 7, the rest having mild/moderate (SGA 3-5, n=118, 21.6%) or severe

198 protein energy wasting (SGA 1-2, n=2, 0.4%). Amongst males mean(+/-sd) age was

63.2(14.1) with height 172.6(7.3)cm, weight 76.2(17.1)kg, and BMI 25.5(5.2)kg/m<sup>2</sup>, 199 whereas amongst females mean(+/-sd) age was 61.9(15.1), with height 200 159.7(8.0)cm, weight 70.0(17.2)kg, and BMI 26.2(6.4)kg/m<sup>2</sup>. One-hundred and three 201 patients (18.8%) had a BMI over 30kg/m<sup>2</sup> (categorised as obese). A diagram 202 illustrating an overview of patient flow through each stage of the study can be found 203 204 in supplementary information (Figure S1). Other characteristics of the whole group, 205 well-nourished and poorly nourished subgroups, are provided in Table 1. This sample was drawn from a total population of 1350 people on haemodialysis (in flux 206 207 over time with new people starting dialysis and some discontinuing due to withdrawal or death or having a transplant). Aside from the participants that were not eligible 208 due to being unable to consent or unable to stand (wheelchair or bedbound), only 209 5.9% declined to take part in the study. 210

211

Amongst the 427 well-nourished participants (aged 18-92, 54% male) mean(+/-sd) HGS was 28.1(10.6)kg with a right-skewed distribution in males and 17.3(6.5)kg in females (Figure 1A). This distribution is however very different from a healthy, nondialysis population: using large population studies from healthy individuals stratified by age and gender <sup>19</sup> or age, gender and height <sup>17</sup>, HGS values in our study are seen to cluster predominantly below the 10<sup>th</sup> percentile (Figure S2 in supplementary information).

219

Demographic variables associated with HGS were explored separately in males and
females with 5-fold cross-validation and showed strong associations with age and
height and gender, and a weaker no consistent association with ethnic background
(Table 2).

	urnal		101	<u>`</u>	
	umar			U.	

<u>ь</u> 1

224	Averages across the five models were used to derive coefficients for a-male and
225	female prediction equations:
226	
227	Predicted HGS(kg) = $0.38$ *height(cm) – $0.31$ *age(years) – 18 (males)
228	= 0.25*height(cm) – 0.11*age(years) – 16 (females)
229 230	HGS index was then defined as the observed HGS relative to this prediction as a
231	percentage:
232	
233	HGS index (%) = 100 x [observed HGS / expected HGS]
234	
235	HGS index in the whole group (N=547, including well and poorly nourished
236	participants) was normally distributed with mean(+/-sd) 98.5(33.9)%. Mean(+/-sd)
237	HGS index in well-nourished patients was 100.4(32.5)% and in malnourished
238	patients was 91.7(37.6)%. The distribution of HGS index was similar in males and
239	females (Figure 1B). As an example, where the observed HGS matches the
240	expected HGS derived from the predictive equation based on demographics of well-
241	nourished individuals on haemodialysis, the HGS index would be 100%. Where the
242	observed is lower than the expected, the HGS index would be less than 100%.
243	
244	In linear regression models, simple HGS is associated strongly with demographic
245	variables (age, gender and height) and with the addition of clinical data (dialysis
246	vintage, diabetes status, albumin, BMI) much of the variation in HGS can be
247	explained ( $R^2$ =0.430) as is shown in Table 3. In contrast HGS index is most closely
248	associated with illness variables (dialysis vintage, diabetes status and BMI), however
249	these variables only mildly influence it ( $R^2$ =0.039, Table 3). In addition, as is

expected, HGS index is not associated with demographic variables as these are 250 included in the prediction equation when calculating expected HGS. Therefore, 251 252 unlike simple HGS measurement which overlaps substantially with the clinical and demographic data, HGS index adds new information reflecting muscle weakness 253 beyond aging and being on haemodialysis. 254 255 Over a mean follow-up duration of 2.8 years (1,530 patient-years total), there were 138 deaths (25.2% of the group). Dividing participants into quintiles of HGS index 256 (with guintile cut-offs at 72, 91, 107 and 126%), higher HGS index guintile at 257 258 baseline predicted longer survival (p=0.023, Figure 2). 259 In Cox Proportional Hazards models, HGS index guintile performed at least as well 260 as simple HGS quintile, as being an independent predictor of survival after 261 adjustment for age, albumin and body mass index (p=0.049, Table 4). Being two 262 quintiles weaker (e.g. being in the lowest vs middle quintile of HGS index) was 263 associated with a 26% increased mortality hazard, equivalent on average to an 264 additional mortality of 2.7%, and equal to the mortality disadvantage of being 4 years 265

older, having 3.2 g/L lower albumin, or 7.5 kg/m<sup>2</sup> lower body mass index.

267

#### 268 Discussion

This study of 547 participants describes the distribution of HGS in people on
haemodialysis and develops a predictive equations for males and females to
determine expected HGS values based on people who are well-nourished. Defining
HGS index as the ratio of observed to expected HGS as a method to determine
degree of weakness, was found to be a strong independent predictor of survival. By
defining what is 'normal for haemodialysis' and having a parameter that represents

т.

individualised as opposed to generic weakness, HGS index facilitates early and rapid
detection of muscle weakness through a single as opposed to serial measurements,
paving the way for potential targeted and timely interventions.

278

This study confirms the near universal presence of muscle weakness in people on 279 280 haemodialysis when compared with similar aged individuals without kidney disease. 281 For example, in a study of 3700 healthy volunteers (mean age 63, range 52 – 82 years) from the English Longitudinal Study of Ageing <sup>34</sup>, investigators reported a 282 283 mean HGS of 42.9 and 26.0kg in males and females respectively, which by comparison with these data suggests that HGS is reduced by approximately 30% 284 even in well-nourished people on haemodialysis, regardless of gender. The 285 comparative distribution illustrated in supplementary information demonstrates the 286 limited utility of assessing weakness in people on haemodialysis compared to a 287 healthy reference range since the vast majority of individuals would be defined as 288 weak. A method specific to people on haemodialysis that more accurately 289 determines degree of weakness, which might respond to targeted intervention, is 290 certainly of value in clinical practice. 291

292

In other studies of people on haemodialysis, similar demographic predictors of HGS
have been observed: in 156 participants from Brazil, Pinto found both height
(R=0.57) and age (R=-0.35) to be closely correlated with HGS, suggesting that these
predictive relationships are reproducible in different haemodialysis populations. In
healthy populations, height is also an important predictor of HGS. With such a
strong contribution from a continuous variable, one approach, for example adopted
by Spruit in a study of over 500 000 participants <sup>17</sup>, is to provide reference ranges

stratified by height. We adopt the alternative strategy, more suited to a smaller 300 population, of defining the expected HGS predicted by demographic variables 301 302 including height and describing observed HGS as a percentage of this prediction (HGS index). This approach is well-established in other areas of clinical nutrition 303 and physiology: target energy requirements, for example, are calculated using 304 305 equations which include age, weight, and ethnicity. Similarly, lung function tests are 306 commonly reported as a percentage of the expected value, predicted by height amongst other variables. The concept of HGS index therefore has reasonable 307 308 precedent in clinical practice.

309

HGS index is (mostly) not predicted by demographic variables as one component of
the index (expected HGS) is already adjusted for age, height and sex.

Demographic variables are mostly not predictive of HGS index since expected HGS 312 313 is already adjusted for these variables. This independence from demographic 314 variables makes HGS index a more meaningful measure of weakness, since simple HGS may be appropriately low due to older age or shorter stature, in the absence of 315 any reduction in strength due to clinical reasons. As expected, Illness variables, 316 such as diabetes status and BMI, however, remain associated with HGS index. 317 HGS index was also found to reduce by 1% for each additional year on 318 haemodialysis (dialysis vintage). HGS declines more rapidly than HGS index over 319 time in people on haemodialysis as it is influenced by aging as well as clinical 320 variables. In Kaysen's paper, males on haemodialysis lost a mean of 3.9% of their 321 HGS over 12 months <sup>35</sup>. 322

323

A similar relationship between HGS and haemodialysis mortality has been observed 324 previously: for example, Matos reported baseline handgrip in 443 adults and 325 326 subsequent mortality over a median follow-up of 34 months, finding 17% increased mortality in those with low HGS compared to those with high HGS <sup>5</sup>. The association 327 has been confirmed also in a meta-analysis in which low HGS was predictive of 328 mortality <sup>36</sup>, and the relationship between reduced muscle mass and poor survival 329 has been observed in a number of settings <sup>37–39</sup>. Muscle strength rather than muscle 330 mass is thought to be the dominant factor, so it is not surprising that HGS would be 331 associated with increased mortality <sup>9,10</sup>. But since there is much co-linearity between 332 HGS and other clinical parameters as well as aging <sup>10,22</sup> it can be difficult to be clear 333 that HGS is indicating something beyond older age and kidney failure. 334

335

HGS index however indicates weakness beyond that to be expected from having
end stage renal disease on treatment. Since HGS index performs as well as simple
HGS as an independent predictor of survival, it can be seen that HGS index captures
the value of HGS yet enhances this further by accounting for individual demographic
values e.g. height, age, as well as quantifying degree of weakness. This makes HGS
index a more useful clinical tool than simple HGS and allows a single measurement
to be clinically meaningful.

343

Being a single centre study enables accurate outcome data and consistency of treatment practices but the external validity is less clear, and it is possible that some of the conclusions are centre specific. In addition, HGS was measured at a single timepoint, with a limited set of other variables available. One challenge in comparing studies is lack of consistency in the method of HGS measurement. Hwang's meta-

analysis describes variability in dynamometer type and calibration, arm side
(dominant vs non-fistula) and position, duplicate measurement and statistical
handling of repeated measures. A recent study determined a standardised method
of HGS assessment, which does differ from our study, which was completed
previously <sup>40</sup>. Our study was however large and broadly inclusive, with reasonable
duration of post-measurement observation, so it is likely that findings are broadly
generalisable.

356

In conclusion, the reduced HGS of people on haemodialysis is influenced by
demographic and clinical variables. HGS index, already demographically adjusted,
reflects mostly clinical weakness and is a strong independent predictor of mortality.
HGS index therefore detects the degree of muscle weakness in people on
haemodialysis, allowing for potential earlier intervention and detection of responses
to therapy. Further research demonstrating the clinical utility of this novel parameter
is anticipated.

#### 365 **Practical applications**

366

- 367 This study illustrates the need for haemodialysis specific reference ranges and
- 368 discusses a novel and demographically adjusted index to interpret handgrip strength
- developed for people on haemodialysis and predictive of survival.
- 370 Handgrip strength has the potential to be implemented routinely in clinical practice
- 371 providing objective and individualised data on muscle weakness derived from a
- reference group of well-nourished people on haemodialysis. Our method enables a
- single (versus ongoing) handgrip strength measurement to provide valuable clinical
- information, which has not been available to date.

375

376

#### 378 Authors' contributions

burnalprophos

### **References**

384	1.	Steenkamp R, Pyart R, Fraser S. UK Renal Registry 20th Annual Report:
385		Chapter 5 Survival and Cause of Death in UK Adult Patients on Renal
386		Replacement Therapy in 2016: National and Centre-specific Analyses.
387		Nephron. 2018;139 (Suppl:117-150.
388	2.	Carrero JJ, Thomas F, Nagy K, et al. Global Prevalence of Protein-Energy
389		Wasting in Kidney Disease: A Meta-analysis of Contemporary Observational
390		Studies From the International Society of Renal Nutrition and Metabolism. $J$
391		Ren Nutr. 2018;28(6):380-392. doi:10.1053/j.jrn.2018.08.006
392	3.	Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and
393		diagnostic criteria for protein – energy wasting in acute and chronic kidney
394		disease. <i>Kidney Int</i> . 2008;73:391-398. doi:10.1038/sj.ki.5002585
395	4.	Isoyama N, Qureshi AR, Avesani CM, et al. Comparative associations of
396		muscle mass and muscle strength with mortality in dialysis patients. Clin J Am
397		Soc Nephrol. 2014;9(10):1720-1728. doi:10.2215/CJN.10261013
398	5.	Matos CM, Silva LF, Santana LD, et al. Handgrip strength at baseline and
399		mortality risk in a cohort of women and men on hemodialysis: A 4-year study. $J$
400		Ren Nutr. 2014;24(3):157-162. doi:10.1053/j.jrn.2013.12.005
401	6.	Chiles Shaffer N, Fabri E, Ferrucci L, Shardell M, Simonsick EM, Studenski S.
402		Muscle quality, strength, and lower extremity physical performance in the
403		Baltimore Longitudinal Study of Aging. J Frailty Aging. 2017;6(4):183-187.
404	7.	Qureshi AR, Alvestrand A, Danielsson A, et al. Factors predicting malnutrition
405		in hemodialysis patients: a cross-sectional study. Kidney Int. 1998;53(3):773-
406		782. doi:10.1046/j.1523-1755.1998.00812.x

407	8.	Norman K, Stobäus N, Gonzalez MC, Schulzke J, Pirlich M. Hand grip
408		strength : Outcome predictor and marker of nutritional status. Clin Nutr.
409		2011;30(2):135-142. doi:10.1016/j.clnu.2010.09.010
410	9.	Vogt BP, Borges MCC, Goés CR de, Caramori JCT. Handgrip strength is an
411		independent predictor of all-cause mortality in maintenance dialysis patients.
412		Clin Nutr. 2016;35(6):1429-1433. doi:10.1016/j.clnu.2016.03.020
413	10.	Leong DP, Teo KK, Rangarajan S, et al. Prognostic value of grip strength:
414		Findings from the Prospective Urban Rural Epidemiology (PURE) study.
415		Lancet. 2015;386(9990):266-273. doi:10.1016/S0140-6736(14)62000-6
416	11.	Rantanen T, Guralnik JM, Foley D, et al. Midlife hand grip strength as a
417		predictor of old age disability. J Am Med Assoc. 1999;281(6):558-560.
418		doi:10.1001/jama.281.6.558
419	12.	Gopinath B, Kifley A, Liew G, Mitchell P. Handgrip strength and its association
420		with functional independence, depressive symptoms and quality of life in older
421		adults. Maturitas. 2017;106(June):92-94. doi:10.1016/j.maturitas.2017.09.009
422	13.	Lamarca F, Carrero JJ, Rodrigues JCD, Bigogno FG, Fetter RL, Avesani CM.
423		Prevalence of sarcopenia in elderly maintenance hemodialysis patients: The
424		impact of different diagnostic criteria. J Nutr Heal Aging. 2014;18(7):710-717.
425	14.	Luz MS, Miranda-serrano B, Antonio L, et al. Sarcopenia and Mortality in Older
426		Hemodialysis Patients. Nutrients. 2022;14(2354):1-13.
427	15.	Dodds RM, Syddall HE, Cooper R, et al. Grip Strength across the Life Course :
428		Normative Data from Twelve British Studies. PLoS One. 2014;9(12):1-15.
429		doi:10.1371/journal.pone.0113637
430	16.	Alley DE, Shardell MD, Peters KW, et al. Grip strength cutpoints for the
431		identification of clinically relevant weakness. Journals Gerontol - Ser A Biol Sci

432		Med Sci. 2014;69 A(5):559-566. doi:10.1093/gerona/glu011
433	17.	Spruit MA, Sillen MJH, Groenen MTJ, Wouters EFM, Franssen FME. New
434		normative values for handgrip strength: Results from the UK biobank. J Am
435		Med Dir Assoc. 2013;14(10):775.e5-775.e11. doi:10.1016/j.jamda.2013.06.013
436	18.	Koopman JJE, van Bodegom D, van Heemst D, Westendorp RGJ. Handgrip
437		strength, ageing and mortality in rural Africa. Age Ageing. 2015;44:465-470.
438		doi:10.1093/ageing/afu165
439	19.	Dodds RM, Syddall HE, Cooper R, Kuh D, Cooper C, Avan Aihie Sayer. Global
440		variation in grip strength: A systematic review and meta-analysis of normative
441		data. Age Ageing. 2016;45(2):209-216. doi:10.1093/ageing/afv192
442	20.	Studenski SA, Peters KW, Alley DE, et al. The FNIH Sarcopenia Project:
443		Rationale, Study Description, Conference Recommendations, and Final
444		Estimates. Journals Gerontol Ser A Biol Sci Med Sci. 2014;69(5):547-558.
445		doi:10.1093/gerona/glu010
446	21.	Lauretani F, Russo CR, Bandinelli S, et al. Age-associated changes in skeletal
447		muscles and their effect on mobility: an operational diagnosis of sarcopenia. $J$
448		Appl Physiol. 2003;95(5):1851-1860. doi:10.1152/japplphysiol.00246.2003
449	22.	Silva LF, Matos CM, Lopes GB, et al. Handgrip strength as a simple indicator
450		of possible malnutrition and inflammation in men and women on maintenance
451		hemodialysis. J Ren Nutr. 2011;21(3):235-245. doi:10.1053/j.jrn.2010.07.004
452	23.	National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic
453		Kidney Disease: Evaluation, Clasification and Stratification. Vol 39.; 2002.
454		doi:10.1634/theoncologist.2011-S2-45
455	24.	Jacobson J, Ju A, Baumgart A, et al. Patient Perspectives on the Meaning and
456		Impact of Fatigue in Hemodialysis: A Systematic Review and Thematic

457 Analysis of Qualitative Studies. *Am J Kidney Dis*. 2019;74(2):179-192.

458 doi:10.1053/j.ajkd.2019.01.034

- 459 25. Pinto AP, Ramos CI, Meireles MS, Kamimura MA, Cuppari L. Impact of
- hemodialysis session on handgrip strength. *J Bras Nefrol*. 2015;37(4):451-457.
- 461 doi:10.5935/0101-2800.20150072
- 462 26. Delanaye P, Quinonez K, Buckinx F, Krzesinski JM, Bruyère O. Hand grip
- 463 strength measurement in haemodialysis patients: Before or after the session?

464 *Clin Kidney J.* 2018;11(4):555-558. doi:10.1093/ckj/sfx139

465 27. Marion R, Niebuhr BR. Effect of Warm-up Prior to Maximal Grip Contractions.

466 *J Hand Ther*. 1992;5:143-146. doi:10.1016/S0894-1130(12)80349-8

- 28. Coldham F, Lewis J, Lee H. The Reliability of One vs. Three Grip Trials in
- 468 Symptomatic and Asymptomatic Subjects. *J Hand Ther*. 2006;19:318-327.
- 469 doi:10.1197/j.jht.2006.04.002
- 470 29. Roberts HC, Denison HJ, Martin HJ, et al. A review of the measurement of grip
- 471 strength in clinical and epidemiological studies : towards a standardised

472 approach. Age Ageing. 2011;40:423-429. doi:10.1093/ageing/afr051

473 30. Ikizler TA, Wingard RL, Harvell J, Shyr Y, Hakim RM. Association of morbidity

474 with markers of nutrition and inflammation in chronic hemodialysis patients: a

475 prospective study. *Kidney Int*. 1999;55:1945-1951.

- 476 31. Steiber A, Leon JB. Multicenter Study of the Validity and Reliability of
- 477 Subjective Global Assessment in the Hemodialysis Population. *Medicine*
- 478 (Baltimore). 2007;17(5):336-342. doi:10.1053/j.jrn.2007.05.004
- 479 32. Stone M. Cross-validatory choice and assessment of statistical predictions. *J R*480 *Stat Soc.* 1974;36(2):111-147.
- 481 33. Mosteller F, Tukey JW. Data analysis, including statistics. In: Handbook of

482		Social Psychology. ; 1968.
483	34.	Syddall H E, Westbury L D, Shaw S C, Dennison E M, Cooper C GCR.
484		Correlates of Level and Loss of Grip Strength in Later Life : Findings from the
485		English Longitudinal Study of Ageing and the Hertfordshire Cohort Study.
486		Calcif Tissue Int. 2018;102(1):53-63. doi:10.1007/s00223-017-0337-5
487	35.	Chiang JM, Kaysen GA, Segal M, Chertow GM, Delgado C, Johansen KL. Low
488		testosterone is associated with frailty, muscle wasting and physical dysfunction
489		among men receiving hemodialysis: a longitudinal analysis. Nephrol Dial
490		<i>Transplant</i> . 2019;34:802-810. doi:10.1093/ndt/gfy252
491	36.	Hwang SH, Lee DH, Min J, Jeon JY. Handgrip Strength as a Predictor of All-
492		Cause Mortality in Patients With Chronic Kidney Disease Undergoing Dialysis:

- A Meta-Analysis of Prospective Cohort Studies. *J Ren Nutr.* 2019:471-479.
- doi:10.1053/j.jrn.2019.01.002
- 495 37. Abramowitz MK, Hall CB, Amodu A, Sharma D, Androga L, Hawkins M.
- 496 Muscle mass, BMI, and mortality among adults in the United States: A
- 497 population-based cohort study. *PLoS One*. 2018.
- 498 doi:10.1371/journal.pone.0194697
- 499 38. Huang CX, Tighiouart H, Beddhu S, et al. Both low muscle mass and low fat
- are associated with higher all-cause mortality in hemodialysis patients. *Kidney*
- 501 Int. 2010. doi:10.1038/ki.2009.524
- 39. Lin TY, Peng CH, Hung SC, Tarng DC. Body composition is associated with
- clinical outcomes in patients with non–dialysis-dependent chronic kidney
- 504 disease. *Kidney Int*. 2018;93(3):753-760. doi:10.1016/j.kint.2017.08.025
- 40. Wilkinson T, Gabrys I, Lightfoot C, et al. A Systematic Review of Handgrip
- 506 Strength Measurement in Clinical and Epidemiological Studies of Kidney

Journal Pre-proof			1.00				
JUUINALI IC-DIUU	111212	<u></u>			A 1	$\sim$	

507 Disease: Toward a Standardized Approach. *J Ren Nutr.* 2021.

508

ournal Pre-proó

	Well-nourish	ned (N=427)	Poorly nour	ished (N=120)	Whole group (N=547)		
	Med(IQR) / N(%)	HGS(kg)	Med(IQR) / N(%)	HGS(kg)	Med(IQR) / N(%)	HGS(kg)	
All patients		22 (16.5-28)		18.5 (12-25)		21 (15.5-28)	
Age (years)	63 (52-75)		65 (53-74)		64 (53-75)		
< 65 > 65	227 (53.2) 200 (46.8)	24 (18-32) 19 (15-25)	58 (48.3) 62 (51.7)	19 (13.5-29) 18 (11-23)	285 (52.1) 262 (47.9)	23 (18-30) 19 (14-25)	
Gender							
Male Female	232 (54.3) 195 (45.7)	27.5 (21-33) 18 (13-21)	50 (41.7) 70 (58.3)	23.5 (17-30) 15 (10-20)	282 (51.6) 265 (48.4)	26.5 (20-32) 18 (12-21)	
Ethnicity							
Black White Asian/other	119 (27.9) 143 (33.5) <mark>165 (38.6)</mark>	24 (18-32) 23 (18-29.5) <mark>20 (16-26)</mark>	26 (21.7) 41 (34.2) 53 (44.2)	19 (12-28) 20 (13-27.5) 16 (11-24)	145 (26.5) 184 (33.5) <mark>218 (39.9)</mark>	22 (17-30) 22 (16.5-29) <mark>19 (14-26)</mark>	
Height (cm)	1.68 (1.60-1.	73)	1.65 (1.57-1.	73)	1.68 (1.59-1.	73)	
< 170 > 170	248 (58.1) 179 (41.9)	18 (14-23) 28 (22-34)	78 (65.0) 42 (35.0)	16 (11-21) 25 (17-31.5)	326 (59.6) 221 (40.4)	18 (14-22) 28 (21-33)	
BMI (kg/m <sup>2</sup> )	25.9 (22.6-29	9.6)	21.8 (19.7-24	1.4)	24.8 (21.7-28	3.9)	
< 25 > 25	184 (43.1) 243 (56.9)	22 (17-28) 21 (16-28.5)	94 (78.3) 26 (21.7)	18 (12-24) 20 (11-28)	278 (50.8) 269 (49.2)	20 (15-28) 21 (16-28)	
Vintage (years)	2.1 (1.0-4.3)		2.5 (1.0-6.2)		2.1 (0.9-4.6)		
< 2 > 2	212 (49.6) 215 (50.4)	23 (16-30) 21 (17-28)	53 (44.2) 67 (55.8)	17 (13-23) 19.5 (11-26)	265 (48.4) 282 (51.6)	21 (15-29) 20.5 (16-28)	
Comorbidity							
Diabetes Vascular	193 (45.2) 103 (24.1)	20 (16-26) 20 (14.5-26)	39 (32.5) 32 (26.7)	16 (11-23) 17 (13.5-21)	232 (42.4) 135 (24.7)	20 (15-26) 20 (14-25.5)	
Albumin (g/L)	35.0 (32.0-38	3.5)	33.5 (31.0-37	7.0)	35.0 (32.0-38	3.0)	
< 35 > 35	196 (45.9) 231 (54.1)	21 (16-27) 22 (18-30)	69 (57.5) 51 (42.5)	19 (13.24) 18 (12-27)	265 (48.4) 282 (51.6)	20 (14-27) 21 (16-30)	

**Table 1.** Patient characteristics and Handgrip Strength in the well-nourished, poorlynourished and whole group.

Characteristics are given as N(%) or median(IQR)

HGS: Handgrip Strength (kg)

	Group	o 1	Group	o 2	Group	5 3	Group	o 4	Group	o 5	Final	model*
Males	Coeff	p value	Coeff	SE								
Height (cm)	.453	.000	.433	.000	.326	.000	.374	.000	.330	.001	0.38	.080
Age (years)	310	.000	253	.000	353	.000	303	.000	345	.000	-0.31	.043
Model fit	R <sup>2</sup>	p value	R <sup>2</sup>	SEE								
Training set	.316	.000	.291	.000	.301	.000	.267	.000	.290	.000		
Validation set	.185	.004	.285	.000	.233	.001	.434	.000	.291	.000	.290	8.94
Females	Coeff	p value	Coeff	SE								
Height (cm)	.263	.000	.247	.000	.193	.001	.307	.000	.235	.000	0.25	.052
Age (years)	086	.009	090	.013	146	.000	093	.004	118	.000	-0.11	.029
Model fit	R <sup>2</sup>	p value	R <sup>2</sup>	SEE								
Training set	.164	.000	.144	.000	.204	.000	.196	.000	.163	.000		
Validation set	.209	.004	.332	.001	.064	.087	.088	.050	.191	.007	.168	5.89

**Table 2.** Prediction of HGS by demographic (non-illness) variables, confirmed by cross-validation in 5 subgroups of well-nourished group (N=427), separated by gender.

Validation group characteristics are given as mean sd or N %, as appropriate.

HSG: handgrip strength

SE: standard error of the coefficient

SEE: standard error of the estimate

\*Final model validated in the complete data set

	Handgr	ip Strengt	h (kg)		Handgrip Strength Index (%)					
	Univari	able	Multiva	riable <sup>a</sup>	Univari	able	Multivariable <sup>b</sup>			
	R	p value	В	p value	R	p value	В	p value		
Age (year)	-0.277	.000	-0.169	.000	0.037	.390		.083		
Gender (Female)	-0.504	.000	-6.637	.000	0.019	.649		.881		
Ethnicity (Black)	0.129	.003		.294	0.061	.153		.305		
Height (cm)	0.537	.000	0.322	.000	-0.019	.655		.662		
BMI (kg/m²)	0.040	.345	0.186	.002	0.107	.012	0.122	.005		
Vintage (year)	-0.097	.024	-0.243	.007	-0.105	.014	-0.118	.007		
Diabetes	-0.119	.005	-2.370	.001	-0.086	.045	-0.128	.004		
Vascular	-0.107	.013		.219	-0.103	.016		.130		
Albumin (g/l)	0.138	.001	0.169	.008	0.111	.010	0.090	.033		

**Table 3.** Demographic and clinical predictors of Handgrip Strength and Handgrip Strength Index in the whole group (N=547)

<sup>a</sup>adjusted  $R^2 = 0.430$  for the final model

<sup>b</sup>adjusted  $R^2 = 0.039$  for the final model

Beta missing for terms excluded from the final model


		Univariable			Multivariable			Multivariable		
					With HGS			With HGS index		
		HR	(95% CI)	p value	HR	(95% CI)	p value	HR	(95% CI)	p value
Age	(year)	1.06	(1.05-1.08)	.000	1.06	(1.05-1.08)	.000	1.06	(1.05-1.08)	.000
Albumin	(g/L)	0.92	(0.89-0.96)	.000	0.92	(0.89-0.96)	.000	0.93	(0.89-0.97)	.000
BMI	(kg/m²)	0.96	(0.93-0.99)	.009	0.96	(0.93-0.99)	.014	0.97	(0.94-0.99)	.029
HGS	(quintile)	0.74	(0.65-0.84)	.000			.053			
HGS index	(quintile)	0.87	(0.77-0.98)	.023				0.89	(0.78-0.99)	.049
Ethnicity	(Black)	0.49	(0.30-0.79)	.004			.250			.303
Vascular		1.49	(1.04-2.12)	.028			.296			.394
Vintage	(year)	1.02	(0.98-1.06)	.290			.382			.467
Gender	(Female)	0.84	(0.60-1.18)	.309			.734			.689
Diabetes		1.20	(0.85-1.68)	.289			.899			.962


**Table 4.** Predictors of survival by Cox Proportional Hazards model in the whole group (N = 547)

Survival censored for moving out of area or at study end, not censored at transplantation HGS: Handgrip strength

HR: hazard ratio

CI: confidence interval





#### Figure 1. Distribution of Handgrip Strength and Handgrip Strength index. (A)

Left panels: Handgrip Strength (simple, without any adjustment) in well-nourished and poorly nourished participants (B) Right panels: Handgrip Strength index (percentage of HGS expected derived from a well-nourished haemodialysis population, adjusted for age, gender and height) in well-nourished and poorly nourished participants. Upper panels: males. Lower panels: females.

**Figure 2. Patient survival by Handgrip Strength index.** Patients were separated by baseline Handgrip Strength Index into quintiles (Q1-Q5) with quintile cutoffs at 72, 91, 107 and 126%. Survival was censored at the end of observation, or at transplantation or transfer to another centre.

#### **Credit Author Statement**

**Tina Dilloway**: Investigation, Resources, Data curation, Writing – Original draft, Project administration, Funding acquisition.

**Damien Ashby**: Formal analysis, Visualization, Writing – review and editing.

Mary Hickson: Conceptualization, Methodology, Writing – review and editing, Supervision.

Ayako Temple: Investigation, Writing - review and editing.

**Lina Johansson**: Conceptualization, Methodology, Investigation, Visualization, Writing – review and editing, Supervision, Funding acquisition.

ourna